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Abstract
Background: Fibrosis can be described as the excess deposition of extracellular matrix (ECM) components, such as 
collagens and proteoglycans. Fibrosis of the liver, which eventually leads to cirrhosis, is a major global health problem. 
Being able to measure fibrosis progression may enable timely preventative intervention. The aim of the current study 
was to investigate the utility of serum procollagen type I N-terminal propeptide (PINP) as a marker of hepatic fibrosis, as 
distinct from bone formation, during three different periods of fibrosis development following hepatic injury induced 
by bile duct ligation (BDL) in rats.
Methods: BDL was performed on 30 female Sprague-Dawley rats aged 6 months, and sham operations on 30 controls. 
Animals were killed after 14, 28, or 35 days. The extent of liver fibrosis was evaluated by quantitative histology after Sirus 
Red staining. Levels of serum PINP and osteocalcin (a marker solely for osteoblastic bone formation) were determined 
using ELISA at baseline and post termination.
Results: Collagen formation increased by 30% compared to 3% in sham-operated animals (P < 0.0001). PINP levels 
increased significantly in all BDL groups compared with baseline (14 days: baseline 13.9 ng/ml, termination 17.7 ng/ml, 
P = 0.047; 28 days: baseline 17.9 ng/ml, termination 26.2 ng/ml, P = 0.005; 35 days: baseline 18.0 ng/ml, termination 27.4 
ng/ml P = 0.015, an increase of 52%). PINP levels did not change from baseline in the sham-operated rats, indicating 
that the increased PINP levels were due to hepatic injury. The bone-specific marker, osteocalcin, did not increase in 
either BDL or sham-operated rats. PINP measured in serum correlated to the extent of liver fibrosis as evaluated by 
quantitative histology (R2 = 0.42, P < 0.001).
Conclusion: PINP was associated with the development of liver fibrosis, but not bone formation, in mature rats 
subjected to BDL. Thus, PINP may be useful in studying the pathogenesis of liver fibrosis. However, caution should be 
applied when interpreting PINP levels in other disease states.
Background
Fibrosis may be described as extensive scar formation,
observed as increased deposition and abnormal distribu-
tion of extracellular matrix (ECM) components, such as
collagen and proteoglycans. Liver fibrosis is a serious
complication of chronic inflammatory liver diseases aris-
ing from diverse infectious, inflammatory or toxic causes
[1]. Progression of fibrosis eventually leads to liver cirrho-
sis, which is a major global health problem accounting for
approximately 800,000 deaths per year worldwide [1-3].
Histopathological examination of liver biopsies is the
gold standard for diagnosis and staging of chronic liver
diseases and is of significance when evaluating the effect
of therapeutic intervention. Liver biopsy, however, has
two significant drawbacks. It is invasive, and prone to
variation in the length and size of the tissue specimen
which leads to low reproducibility and high intrapatient
variation [4,5]. Therefore, the development of non-inva-
sive biomarkers of fibrogenesis may be important for the * Correspondence: ssv@nordicbioscience.com
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staging and monitoring of chronic liver disease, and may
provide additional information on the pathogenesis.
Matrix remodelling is a normal integrated process of
tissue homeostasis and maintenance but it changes under
certain disease conditions [6,7]. The central pathological
feature of fibrosis is uncontrolled ECM remodelling [4-
6,8,9]. The liver ECM is composed mainly of fibrous pro-
teins such as collagens and proteoglycans [6,7,10]. During
fibrogenesis the quality, quantity, and distribution of the
ECM in the liver changes, which results in excessive accu-
mulation of fibrous tissue (that is, scar tissue), and an
overall increase in ECM density [6,7,10]. A cirrhotic liver
may contain up to six times more collagen than that of a
healthy liver [6-8,11].
The formation and degradation of ECM components is
accompanied by the release of protein breakdown prod-
ucts into the circulation [7,12]. Thus, circulating levels of
these byproducts may potentially be used as biochemical
markers for assessing the extent of disease and prognosis,
and for monitoring response to treatment [13]. Although
several biomarkers such as hyalronic acid, collagen mark-
ers, and laminin are available for diagnosis and follow-up
of liver fibrosis, the accuracy of these biomarkers for
detection of fibrosis is highly variable [4,5].
In the healthy human liver the most abundant collagens
are the fibril-forming types I and III. Fibril-forming colla-
gens are synthesised as precursor molecules with large
propeptide extensions at both the N-terminal and C-ter-
minal of the molecule [14]. The mature propeptides are
cleaved from procollagen by N-terminal or C-terminal
proteinases, and mature collagen is integrated into the
ECM [8,15,16]. During fibrogenesis, type I collagen levels
increase up to eightfold [4,5,9,17]. Notably, type I colla-
gen levels increase significantly more than type III,
changing the ratio from 1:1 in the healthy liver to 1:2 in
the cirrhotic liver [4,5,9,17]. Measuring serum levels of
the procollagen type I N-terminal propeptide (PINP)
released during collagen formation may be useful as a
marker of fibrogenesis, either alone, in ratios or in combi-
nation with other techniques.
Several animal models for liver fibrosis have been
developed, most of them using small rodents [11], each
with individual strengths and weaknesses. Bile duct liga-
tion (BDL) has been used as an animal model of chronic
liver injury due to its resemblance to hepatocyte damage,
hepatic stellate cell activation, and liver fibrosis observed
in human cholestatic liver disease [18]. Even though a
range of investigators have used BDL rats as models of
liver fibrosis, the measurement of serological biochemical
markers of liver ECM turnover has not been presented.
This may in part be due to the lack of procollagen mark-
ers for rodent use. The current study is, to our knowl-
edge, the first to use the type I collagen turnover marker,
PINP, to monitor the development of liver fibrosis in BDL
rats. In contrast to previous researchers, we used mature
rats of 6 months of age, because in young rodents colla-
gen turnover is highly elevated during skeletal growth
and remodelling of the growth plate [12].
B o n e  t u r n o v e r  c a n  b e  m e a s u r e d  b y  s e r o l o g i c a l  b i o -
chemical markers [13]. Bone formation can be assessed
by both type I collagen propeptides and osteocalcin,
which is synthesised and secreted by osteoblasts during
bone formation [12]. Collagen type I constitutes 90% of
bone, but it is also present in many other tissues includ-
ing liver, skin and tendons [19-21]. In contrast, osteocal-
cin is one of the major non-collagenous proteins of bone
constituting approximately 50% of the total non-collage-
nous proteins [12], and is considered more bone specific.
The aim of the current study was to investigate whether
PINP levels, indicating collagen type I formation, could
be a potential marker for liver fibrosis in an experimental
model. We compared levels of PINP with those of osteo-
calcin, a bone-specific marker, to investigate the specific-




A total of 60 female Sprague-Dawley rats aged 6 months
were housed at the animal research facilities at Nordic
Bioscience, Denmark. The experiments were approved by
the Experimental Animal Committee of the Danish Min-
istry of Justice, and were performed according to the
European Standard for Good Clinical Practice (2008/561-
1450). The rats were housed in standard type III-H cages
at 18°C to 22°C with bedding and nest material (Altromin
1324; Altromin, Lage, Germany) and purified water
(Milli-Q system; Millipore, Glostrup, Denmark) ad libi-
tum. Rats were kept under conditions of a 12-h light: dark
cycle. Experiments began after 1 week of acclimatisation.
Liver fibrosis was induced in anaesthetised rats by stan-
dard BDL in which the bile duct was ligated in two places
and dissected between the ligations prior to closing the
abdomen. In sham-operated rats, the abdomen was
closed without BDL.
Study design
The rats were divided into three groups: group 1 (10 BDL
and 10 sham-operated rats) were killed after 2 weeks,
group 2 (10 BDL and 10 sham-operated rats) were killed
after 4 weeks, and group 3 (10 BDL and 10 sham-oper-
ated rats) were killed after 5 weeks. The procedure began
with fasting the animals for at least 14 h, after which they
were asphyxiated by CO2 and killed by exsanguination.
Blood sampling
Blood samples were taken under light CO2/O2 anaesthe-
sia at baseline and at termination from the retro-orbitalVeidal et al. Fibrogenesis & Tissue Repair 2010, 3:5
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sinus of rats that had fasted for at least 14 h. The collected
blood was left for 30 min at room temperature to clot, fol-
lowed by centrifugation at 1500 g for 10 min. All clot-free
liquid was transferred to new tubes and centrifuged again
at 1500 g for 10 min. The serum was then transferred to
clean tubes and stored at -80°C until analysis was per-
formed.
Tissue handling
After the rats were killed, their livers were carefully dis-
sected, weighed, fixed in 4% formaldehyde for a mini-
mum of 24 h, cut into appropriate slices and embedded in
paraffin. Sections 5 μm thick were cut, mounted on glass
slides and stained with Masson's trichrome. The liver sec-
tions were evaluated histologically by assessment of the
architecture, presence of inflammation, proliferation of
bile ducts and fibrosis. The de novo bile duct formation in
the parenchyma was evaluated semiquantitatively using
the following scoring system: normal = 0, mild changes
(one-third or less of the lobule affected) = 1, moderate
changes (between one-third and two-thirds of the lobule
affected) = 2, and severe changes (two-thirds or more of
the lobule affected) = 3. Digital photographs were taken
using an Olympus B × 60 microscope with × 40 and × 100
magnification and an Olympus 5050-zoom digital camera
(Olympus, Tokyo, Japan).
Histology image analysis
Histology sections stained with Sirus Red were analysed
using Visiopharm software V. 3.2.8.0 (Hørsholm, Den-
mark). Images were acquired using a PixeLINK PL-
A623C microscope digital camera (PixeLINK, Ottawa,
Canada).
Immunohistochemistry
Liver sections (5 μm) were deparaffinised, hydrated and
further peroxidase activity was blocked with the addition
of 0.4% hydrogen peroxide. Sections were then incubated
with a polyclonal antibody against type I collagen (1:10;
Abcam, Cambridge, UK). Sections were then rinsed and
the antibody binding was depicted using the Super Sensi-
tive Polymer-HRP IHC Detection System combined with
AEC substrate, according to the supplier's instructions
(Biogenex, Taby, Sweden). Sections were counterstained
with Mayer's haematoxylin. Pictures were taken at × 33
magnification as described above.
Determination of serum PINP and osteocalcin
The concentration of PINP was assayed using a commer-
cial Rat PINP ELISA Kit (IDS Nordic, Herlev, Denmark),
and osteocalcin was assayed using the commercial Osteo-
calcin ELISA kit (IDS Nordic). All samples were assayed
in duplicate.
Statistical analysis
Mean values and standard error of the mean (SEM) were
calculated using GraphPad Prism (GraphPad Software,
San Diego, CA, USA) and statistical significance assessed
using the Student two-tailed paired t test (α = 0.05),
assuming normal distribution, or the Mann-Whitney
two-tailed non-parametric test (α = 0.05). The coefficient
of correlation (R2) and the corresponding P value were
determined by linear regression.
Results
Animals
During the 5 weeks, 6 of 60 rats, all of them BDL oper-
ated, were killed due to excessive weight loss.
Gross liver appearance and histopathological findings
At the time of death, the livers of control animals showed
normal gross morphology while the livers of BDL animals
were enlarged. Mean liver weights were significantly
increased in BDL rats compared to the sham-operated
controls (group 1: sham 8.1 g, BDL 14.1 g; group 2: sham
9.0 g, BDL 19.4 g; group 3: sham 10.3 g, BDL 19.3 g) (Fig-
ure 1a). Semiquantitative scoring of liver sections using
Figure 1 Rat liver results. (a) Liver weight in bile duct ligated (BDL) or 
sham-operated rats. Data are shown as mean ± standard error of the 
mean (SEM). ***P < 0.0001. (b) Scoring of the structural changes in the 
livers of each group. Data are shown as mean ± SEM. (c) Masson's 
trichrome photomicrographs showing the hepatic structure in rats 5 
weeks after a sham operation (c2), 2 weeks after BDL (c3), 4 weeks after 
BDL (c4) and 5 weeks after BDL (c5). The structure of the hepatic lob-
ules around the portal tract (arrows) is clearly disrupted in the BDL rats 
compared with the sham-operated rats. (d) Immunohistochemical 
analysis of type I collagen. Type I collagen is localised around fibrotic 
structures. Original magnification × 40 or × 100.Veidal et al. Fibrogenesis & Tissue Repair 2010, 3:5
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the 0-3 scale showed significantly more structural
changes of the livers in groups 2 and 3 compared to group
1 (Figure 1b). Histological examination of the livers of
sham-operated animals showed they were microscopi-
cally normal, with no sign of fibrosis (Figure 1c, panels 1-
4). In BDL livers, a marked ductal proliferation was
observed. In group 1 (Figure 1c, panels 5-8) the prolifera-
tion was located around the portal tract while in group 3
(Figure 1c, panel 8) the proliferation had spread. Collagen
deposition was found around the ductular structures
(Figure 1c, panels 5-8). Inflammation was minimal and
confined to the portal tracts. No other signs of cholestasis
were seen, whether intracellular cholestasis, bile plugs,
bile infarction or hepatocytic rosette formation.
By immunohistochemistry, collagen type I deposition
was found exclusively in the venous wall of healthy rats
(Figure 1d). In contrast, in group 3 rats in which marked
ductal proliferation was seen around the portal tract with
the formation of multiple neo-bile ducts, more extensive
type I collagen was found (Figure 1d, panel 1).
Serological markers of PINP and osteocalcin
PINP levels increased significantly in all BDL groups
compared with baseline (group 1: baseline 13.9 ng/ml,
termination 17.4 ng/ml; group 2: baseline 17.9 ng/ml, ter-
mination 26.2 ng/ml; group 3: baseline 18.0 ng/ml, termi-
nation 27.4 ng/ml) (14 days: P = 0.047; 24 days: P = 0.005;
35 days: P = 0.015; with the maximum increase of 52%
seen in group 3) (Figure 2a). PINP levels did not change
significantly in the sham-operated rats (Figure 2a).
In contrast to PINP, the bone-specific marker osteocal-
cin did not increase from baseline in BDL or in sham-
operated rats during the study period, nor did it differ
over time following BDL (Figure 2b).
Total collagen increase
The extent of liver fibrosis was evaluated quantitatively
by measuring the extent of Sirus Red staining, as an indi-
cation of the total collagen deposition. Sections stained
with Sirus Red and quantified using Visiopharm software
revealed increased collagen content over time in the
BDL-operated rats (Figure 3a). The red colour in the
mask representing collagen was quantified using the
same software (Figure 3b) and confirmed a significant
increase in total collagen content in BDL-operated rats
compared with sham-operated rats (group 1, P = 0.008;
group 2, P = 0.0006; group 3, P < 0.0001).
Correlations of measured quantitative parameters
To further examine the relationship between PINP and
total collagen increase in liver fibrosis the two parameters
were evaluated by quantitative histology and linear corre-
lation was performed. This revealed a highly significant
correlation with R2 = 0.42 and P < 0.0001 (Figure 3c). This
suggests that collagen type I is an important molecule in
the pathogenesis of liver fibrosis. No correlation between
changes in PINP levels and osteocalcin levels was
detected in the two treatment groups (data not shown).
Discussion
M a t r i x  r e m o d e l l i n g  i s  a n  i n t e g r a t e d  p r o c e s s  o f  t i s s u e
development, maintenance and repair. The key constitu-
ents of ECM in the liver are collagens and proteoglycans,
each with their own unique biophysical properties. In
fibrosis, the most abundant molecules in the ECM are
various forms of collagens, in particular type I and III, as
well as a range of proteoglycans. During fibrogenesis,
type I collagen increases significantly and turnover mark-
ers of this protein may be potential biomarkers of liver
tissue metabolism.
The present study is the first to demonstrate that
hepatic collagen formation in BDL rats can be measured
in the circulation. Rises in PINP serum levels of up to 52%
in BDL rats, indicating increases in type I collagen forma-
tion, were shown to be correlated with the extent of liver
Figure 2 Procollagen and osteocalcin levels. (a) Serum procollagen 
type I N-terminal propeptide (PINP) levels in bile duct ligated (BDL) or 
sham-operated rats. Data are shown as mean ± standard error of the 
mean (SEM). (b) Serum osteocalcin levels in bile duct ligated (BDL) or 
sham-operated rats. Data are shown as mean ± SEM.Veidal et al. Fibrogenesis & Tissue Repair 2010, 3:5
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fibrosis (R2  = 0.42, P  < 0.001). Histological staining
showed extensive liver fibrosis in the BDL groups, with a
total collagen content of more than 20% in some rats, and
an average increase over control of more than 10 times.
Immunohistochemistry of type I collagen confirmed
extensive deposition of type I collagen in disease-
affected, but not healthy, livers. Type I collagen was
mainly present around neo-bile ducts. Previous investiga-
tors have demonstrated that type I collagen is increased
significantly in various animal models of liver fibrosis
[4,5,8,11], and the current data are in agreement with the
notion that type I collagen is the predominant collagen in
liver fibrosis.
Both bone and fibrotic livers are major sources of type I
collagen turnover and it is important to distinguish
between sources when trying to determine the relative
contribution of each tissue to systemic levels of circulat-
ing PINP. The organic matrix in bone consists of approxi-
mately 90% type I collagen, while the remaining 10% is
composed of proteoglycans and numerous non-collage-
nous proteins, of which osteocalcin and osteonectin con-
stitute 40% to 50% [22,23].
Bone is a high turnover tissue, resulting in the entire
skeleton being totally remodelled in approximately 10
years. Different experiments have suggested that PINP is
a valid bone-formation marker [12], however the present
and other studies suggest that PINP is also present in
many other tissues such as skin, lung, tendons and liver
[18,24,25]. Our experiment suggests that PINP was spe-
cific for the hepatic injury, since the bone-specific marker
osteocalcin did not increase in BDL rats or in the sham-
operated rats. In addition, no correlation between
changes in PINP levels and osteocalcin levels was
detected in the two treatment groups (data not shown),
indicating that the increased PINP associated with liver
fibrosis was not correlated to bone formation measured
by osteocalcin.
PINP is currently used to monitor the response to para-
thyroid hormone (PTH) treatment for osteoporosis [12].
Our findings may have two implications for such moni-
toring: (1) PINP levels may not be bone specific and as
such may overestimate efficacy of PTH therapy, (2) PTH
may have extraskeletal effects on many tissues in which
collagen type I is turned over. On the basis of our find-
ings, further investigation is warranted to determine
whether more bone-specific markers, such as osteocal-
cin, may more accurately reflect bone metabolism in
response to PTH treatment.
Bone loss has been reported previously to be a compli-
cation of liver fibrosis [26-29]. Total bone mass results
from a balance between bone resorption and bone forma-
tion. In the present study we did not detect from osteo-
calcin measurements large changes in bone formation,
even in the presence of severe liver fibrosis. This suggests
that the decreased bone mass and quality observed by
other investigators [27,30] in liver fibrosis may be driven
by an increase in bone resorption, as previously suggested
in patients with liver cirrhosis secondary to viral infection
[31]. This is in agreement with the notion of poor nutri-
ent uptake in cases of liver fibrosis, and subsequent
increased compensatory calcium reabsorption from the
bones, leading to increased bone resorption [30]. Inter-
Figure 3 Histology and collagen. (a) Top panel: histology sections 
from bile duct ligated (BDL) or sham-operated rats stained with Sirus 
Red as viewed by conventional light microscopy (top row) and after 
masking (bottom row), showing red colour in areas with collagen and 
blue in the parenchyma. Bottom panel: Masked histology sections for 
quantifying total collagen content (red colour) in the liver. (b) Correla-
tion of serum procollagen type I N-terminal propeptide (PINP) and per-
centage liver content collagen. (c) Total collagen quantified by 
Visiopharm software for each group.Veidal et al. Fibrogenesis & Tissue Repair 2010, 3:5
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estingly, the decrease in bone formation in the BDL-oper-
ated animals in group I, which may be considered the
m o r e  a c u t e  r e s p o n s e  t o  s u r g i c a l  t r e a t m e n t ,  s h o w e d  a
decrease in bone formation, whereas the other groups did
not display differences. This is somewhat in agreement
with earlier findings demonstrating decreases in bone
formation in patients [32] and in animals [30].
The present experiments were conducted in mature
rats, which is the gold standard for bone metabolic dis-
eases due to the very high bone turnover in younger rats
[12]. This unique experimental design in the rat liver
fibrosis model allowed for better discrimination of the
tissue source of the biochemical marker than may have
b e e n  p o s s i b l e  w i t h  y o u n g e r  a n i m a l s .  I t  h a s  p r e v i o u s l y
been published that the collagen turnover profile in rats is
highly dependent on age, in which, for example, collagen
type II degradation marker levels decreased from 850 μg/
mmol at 1 month of age to 1 μg/mmol at 6 months of age
[33]. Similar age-dependent profiles have been reported
for type I collagen formation [34].
Our study has some limitations. As PINP propeptides
in part are cleared by liver endothelial cells, and these
cells may be injured secondary to inflammation due to
the BDL, a part of the observed increase could be due to
failure of damaged endothelial cells to clear PINP [35]. As
an example, patients presenting with alcoholic liver fibro-
sis with acute inflammation, N-terminal propeptide of
type III collagen (PIIINP), a marker of type III collagen
formation, is significantly increased, whereas in cirrhosis,
PIIINP is only moderately increased [8]. This increased
level of PIIINP may both be due to impaired clearance
but also the inflammation process itself, as collagen type
III is present in arteries and synovium that are highly
inflamed. As the level of any serological biochemical
marker reflects a balance between formation and clear-
ance, this issue deserves further attention.
Conclusions
In summary, we provide evidence that a collagen type I
turnover product, PINP, is a potential marker for moni-
toring fibrosis during chronic liver disease. Additional
research in well controlled clinical settings is needed to
further investigate this finding.
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